Welcome back. The meeting is now resumed.
The business before us at this time is on an emergency situation facing Canadians in light of the COVID-19 pandemic. Since this is a motion relating to the Patent Medicines Prices Review Board study, it's not related; it's not directly derived from this business.
I'm going to move it out of order at this time.
We did get a notice of motion, and it's certainly acceptable as a notice of motion.